EntryPoint Capital LLC Purchases 2,953 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

EntryPoint Capital LLC raised its position in GeneDx Holdings Corp. (NASDAQ:WGS) by 32.1% in the fourth quarter, HoldingsChannel reports. The fund owned 12,141 shares of the company’s stock after purchasing an additional 2,953 shares during the quarter. GeneDx makes up approximately 0.4% of EntryPoint Capital LLC’s holdings, making the stock its 6th largest holding. EntryPoint Capital LLC’s holdings in GeneDx were worth $933,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. William Blair Investment Management LLC bought a new stake in GeneDx during the 4th quarter valued at $51,496,000. Fred Alger Management LLC bought a new stake in shares of GeneDx during the third quarter worth about $16,731,000. Zweig DiMenna Associates LLC acquired a new stake in shares of GeneDx in the 4th quarter worth about $23,788,000. Raymond James Financial Inc. bought a new position in GeneDx in the 4th quarter valued at about $20,371,000. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in GeneDx during the 3rd quarter valued at about $7,533,000. Institutional investors own 61.72% of the company’s stock.

Insider Buying and Selling

In other news, CEO Katherine Stueland sold 1,078 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $89.44, for a total value of $96,416.32. Following the sale, the chief executive officer now owns 6,674 shares of the company’s stock, valued at $596,922.56. The trade was a 13.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Kevin Feeley sold 1,430 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $76.04, for a total transaction of $108,737.20. Following the completion of the transaction, the chief financial officer now directly owns 26,770 shares of the company’s stock, valued at approximately $2,035,590.80. This trade represents a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 127,735 shares of company stock valued at $11,719,787. 27.30% of the stock is owned by company insiders.

GeneDx Stock Down 1.1 %

WGS stock opened at $103.19 on Tuesday. GeneDx Holdings Corp. has a 1-year low of $8.10 and a 1-year high of $115.60. The stock has a market cap of $2.90 billion, a P/E ratio of -52.65 and a beta of 1.91. The stock’s fifty day simple moving average is $85.25 and its two-hundred day simple moving average is $72.73. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.66. The company had revenue of $95.64 million during the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on WGS shares. The Goldman Sachs Group increased their price objective on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen raised their price objective on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, GeneDx presently has a consensus rating of “Moderate Buy” and a consensus target price of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.